Minerva Neurosciences Inc

Minerva Neurosciences insider buying signals optimism for its Phase 3 roluperidone trial and potential market upside, with executives betting on positive FDA/EMA outcomes.

Minerva Neurosciences insider buying signals confidence ahead of Phase‑3 roluperidone success, while market volatility and reimbursement prospects shape investor outlook.